The PFP products protect medicines from contamination. They include a combination of a formulation without chemical preservatives, a pump system that filters or blocks the returning air, and an actuator that prevents bacterial ingress into the dispenser.
MWV says the five-fold mechanical protection system assures germ-free pump dosing to the patient. It includes non-return valves next to the orifice bore and in the metering chamber, and a filter element for contamination-free ventilation of the container, a locked actuator, and a sealed air path during storage.
The PFP T delivers volumes from 0.05mL to 0.14mL. Upside down and tamper-evident features are also available with the product.
‘We are expanding the range of preservative free pumps to meet consumer demand for preservative-free formulations,’ said Chris Hall, vice president and managing director, Medical Plastics Division, MWV Healthcare.
‘This technology does more than protect preservative free medicines from contamination, it is also suitable for use with other topical or dermal products where protecting the formulation and maintaining sterility is important, and necessary.’
MWV Healthcare expands preservative free pumps line
Manufacturing facility awarded certification for PFP spray systems
You may also like
Trending Articles
Upcoming event
You may also like
Drug Delivery
How are biotech companies using microspheres to go beyond oncology?
Biotech companies are increasingly using microsphere drug delivery technology to expand advanced therapies beyond traditional cancer treatments. In oncology, microspheres (e.g. drug-eluting beads) have been used to localise chemotherapy and reduce side effects
Drug Delivery
Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma
The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic blood-brain barrier transporter approaches. The results also suggest strong support for therapeutically relevant clinical effects of semaglutide using MetP Pharma’s DDT
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies